Agios Pharmaceuticals Inc AGIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Treatment
-
Agios Pharmaceuticals Shares Rise After FDA Grants Priority Review for Sickle Cell Disease Treatment
-
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Trading Information
- Previous Close Price
- $39.92
- Day Range
- $39.04–40.00
- 52-Week Range
- $22.25–45.99
- Bid/Ask
- $39.76 / $40.10
- Shares Outstanding
- 59.47M
- Market Cap
- $2.35B
- Volume/Avg
- 39,191 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 3.53
- Price/Sales
- 35.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 540
- Website
- https://www.agios.com
Valuation
|
Metric
|
AGIO
|
|---|---|
Price/Earnings (Normalized) | 3.53 |
Price/Book Value | 2.14 |
Price/Sales | 35.24 |
Price/Cash Flow | — |
Price/Earnings
AGIO
Financial Strength
|
Metric
|
AGIO
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 14.19 |
Interest Coverage | — |
Quick Ratio
AGIO
Profitability
|
Metric
|
AGIO
|
|---|---|
Return on Assets (Normalized) | −26.54% |
Return on Equity (Normalized) | −28.49% |
Return on Invested Capital (Normalized) | −31.56% |
Return on Assets
AGIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|QPtdTR | LOCK|shC! | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^c&%@> | LOCK|%l!% | $69B | |||
| argenx SE ADR
ARGX
| LOCK|Tg^Gx^ | LOCK|>&% | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|bmDst# | LOCK|f!mx | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Rs%jJ!Z | LOCK|!h | $36B | |||
| Moderna Inc
MRNA
| LOCK|>Yb!%@f | LOCK|>?y | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>c%%w@?d | LOCK|Wgbc | $25B | |||
| Incyte Corp
INCY
| LOCK|Pd$@KL | LOCK|?&^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|lM$##c& | LOCK|KC | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|MpYPPC | LOCK|$>& | $16B |
United States